MDA-MB-157 Xenograft Model Service for Breast Cancer

The MDA-MB-157 xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting hyper-aggressive, metastatic triple-negative breast cancers (TNBC) exhibiting claudin-low and mesenchymal characteristics. Alfa Cytology provides a comprehensive, end-to-end MDA-MB-157 xenograft model service, integrating fully authenticated cellular assets with standardized procedural and inoculation protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-157 Xenograft Model for Breast Cancer

The MDA-MB-157 cell line is a highly specialized and molecularly defined human mammary carcinoma model, clinically valued for studying the claudin-low molecular subtype of triple-negative breast cancer (TNBC). Originally isolated from the pleural effusion of a patient with metastatic breast adenocarcinoma, this model lacks expressions of estrogen receptor alpha (ER-alpha), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. Notably, MDA-MB-157 cells exhibit a distinct mesenchymal-like, spindle-shaped morphology and possess gene expression profiles enriched for epithelial-to-mesenchymal transition (EMT) markers and stem-cell-like traits. These biological hallmarks make the MDA-MB-157 model an indispensable preclinical test matrix for investigating tumor migration, invasion pathways, and for validating novel small-molecule inhibitors, anti-metastatic compounds, and advanced immunotherapeutic interventions.

When established in vivo as a xenograft in immunodeficient mice, MDA-MB-157 cells form solid, poorly differentiated tumors that accurately recapitulate the high-grade histological architecture and aggressive clinical course of human receptor-negative malignancies. To overcome characteristically complex growth dynamics inherent to mesenchymal-like lines and ensure stable tumor propagation, precise cell preparation and calibrated biological matrix supports are systematically required.

Fig 1. Analysis of G2/M cell cycle arrest under PTX in MDA-MB-157 & APC shRNA1 cells. (Astarita EM, et al., 2021)

Cell Line Information: MDA-MB-157

The MDA-MB-157 cell line maintains a distinct spindle-shaped, mesenchymal morphology in vitro and reliably preserves its triple-negative receptor profile and migratory genomic signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-157 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in claudin-low/mesenchymal-like triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-157 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-157 xenograft model:

• Cell Culture & Quality Control: MDA-MB-157 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on study design and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-157 cells is prepared and blended with a verified biological matrix carrier to enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-157 Xenograft Model Construction Workflow

Case Study - MDA-MB-157 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-157 xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule inhibitor targeting mesenchymal tumor proliferation and EMT pathways in triple-negative breast cancer. Under optimized modeling conditions, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent primary tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your aggressive, mesenchymal-like triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, mesenchymal-like triple-negative breast cancer using the robust MDA-MB-157 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.